Thailand's April 30 Cannabis Licence Crackdown Meets Europe's Accelerating Demand: What Exporters Must Understand Now

Two things happened in the Thai cannabis space this month that, taken together, define the situation for any serious exporter right now. On April 30, 2026, the Thai Ministry of Public Health published Ministerial Regulation No. 2 B.E. 2569 in the Royal Gazette, effective immediately. It fundamentally restructures who can hold a cannabis licence in Thailand. At the same time, Europe's medical cannabis market is accelerating at a pace that has surprised even optimistic analysts, with new capital, new country openings, and consolidation deals moving fast. The two stories are directly connected, and understanding them together is more useful than reading either one in isolation.

What the April 30 Regulation Actually Does

The new ministerial regulation amends the foundational 2016 licensing framework that governed all controlled herbs, including cannabis. The critical change is in who qualifies as a licence applicant. Under the previous framework, the category of eligible businesses was broader. Under the April 30 regulation, new cannabis licence applications for activities including study, research, export, distribution, and commercial processing are restricted to legally registered healthcare facilities, pharmacies, herbal product manufacturers and distributors, and the workplaces of licensed traditional healers.

The practical meaning of this is straightforward: standalone cannabis retail shops, unlicensed processors, and operators whose business model was built on the 2022 decriminalization boom cannot obtain new licences under the current rules. They also face significant pressure at renewal. Around 12,000 cannabis distribution licences are due to expire in 2026 and 2027, with approximately half expiring this year. Those renewals will be evaluated under the new criteria. Operators unable to demonstrate a qualifying business structure will not renew successfully.

The regulation also introduces operational requirements that go beyond business-type eligibility. Licensed premises must be located on property the applicant owns or has legal rights to occupy. Odour and smoke elimination systems are now mandatory. Storage areas must be appropriately sized with cannabis stored separately from other products to prevent contamination. These are meaningful infrastructure requirements that the recreational-era shops were not designed to meet.

The Export Licence Dimension

Export licences are explicitly listed among the activities covered by the new regulation. This matters for any cultivator or processor who is pursuing or currently holds an export-linked licence. The entity holding that licence, or applying for one, must now fit the qualifying business profile under the new rules.

For cultivators operating under DTAM GACP certification and pursuing export channels, the business structure question is not abstract. If your operating entity does not clearly fit within the eligible categories, a licence renewal or new export-focused application is at risk. This is a compliance review item that needs to be addressed before the renewal deadline arrives, not after.

DTAM GACP certification itself remains a separate and continuing requirement. As of early 2026, approximately 217 farms held DTAM GACP certification out of more than 11,800 legacy-licensed operators. The April 30 regulation does not change the GACP certification requirement. It layers an additional business-type qualification on top of it. Certified farms whose operating entity does not qualify under the new licence framework face a structural problem that GACP certification alone does not solve.

Europe Is Not Waiting for Thailand to Sort Itself Out

While Thailand's domestic industry consolidates under pressure, the market that most Thai exporters are targeting is moving at a different pace. Europe's licensed medical cannabis sector has entered what analysts are now describing as a buildout phase rather than an exploratory one. Germany remains the largest single market, with patient numbers that have grown dramatically since the implementation of the German Cannabis Act in 2024 and imports that more than doubled from roughly 32,500 kilograms in 2023 to over 72,000 kilograms in 2024. Revenue from the German medical cannabis market was estimated at around 420 million euros in 2024, with projections toward 1 billion euros by 2028.

The consolidation activity is telling. Organigram's acquisition of German operator Sanity for 250 million euros signals that established international operators view the European market as mature enough to justify major capital deployment. That kind of acquisition price reflects confidence in durable demand and regulatory stability, not speculative positioning. The UK, Portugal, Italy, France, Switzerland, and the Czech Republic are all active as either growing import markets, expanding production bases, or both. Poland, the fifth most populous country in Europe, has moved to double its medical cannabis import limit in response to steady domestic demand growth.

For Thai exporters, the relevant question is not whether Europe wants compliant medical cannabis. It clearly does, at scale, and demand continues to outpace the supply of genuinely certified product. The question is whether Thai operators can document their compliance path clearly enough to compete for that demand alongside established producers in Portugal, Australia, Germany, and Colombia.

What the April 30 Regulation Means for International Buyers

European and Australian importers conducting supplier due diligence on Thai partners need to factor the April 30 regulation into their assessment process. A Thai counterparty whose licence is tied to a business structure that does not qualify under the new rules is a supply chain risk. Licences that are due for renewal in 2026 and fail to renew disrupt supply relationships and create documentation gaps that complicate import authorization on the buyer's side.

The positive framing of this is real: the regulation is eliminating non-serious operators. The Thai supply base is contracting toward a smaller number of properly licensed, healthcare-linked, GACP-certified businesses. For buyers who want auditable, sustainable Thai supply relationships, a smaller certified pool with clearer business structures is easier to qualify and maintain than a large pool of inconsistently structured operators. The consolidation is painful for the Thai industry in aggregate. For the subset of operators who survive it compliantly, the competitive position improves.

What to Do Now if You Are a Thai Cultivator or Exporter

The immediate priority is a licence structure review. Check whether your current operating entity qualifies as an eligible business type under the April 30 regulation. If you hold or are applying for an export licence, verify that the licence-holding entity will satisfy the new criteria at renewal. If there is a mismatch, the time to address it is now, not in the weeks before renewal.

The second priority is GACP documentation. EU-GACP readiness, ideally supported by an internationally recognized third-party audit such as CUMCS, remains the minimum that European buyers with serious compliance programs require. Thai GACP certification from DTAM is necessary for domestic legality but is not, on its own, sufficient to satisfy the due diligence expectations of European pharmaceutical-channel importers. These are parallel tracks. The April 30 regulation handles the domestic licence structure. Your EU-GACP compliance documentation handles international buyer confidence. Both need to be in order simultaneously.

DeeMED Consulting supports Thai cultivators and manufacturers through EU-GACP readiness assessments, SOP development, and export licence strategy, including structure reviews against the updated regulatory framework. If your licence renewal is approaching or your export pathway is under review, contact us before the renewal window closes.